10x Genomics (TXG) Cost of Revenue (2018 - 2026)

10x Genomics (TXG) has 9 years of Cost of Revenue data on file, last reported at $44.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 9.65% year-over-year to $44.7 million; the trailing twelve-month figure through Mar 2026 stood at $194.2 million (down 1.76% YoY), and the FY2025 full-year result was $198.9 million, up 1.34% from the prior year.
• Cost of Revenue fell to $44.7 million in Q1 2026, from $53.0 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $68.2 million in Q4 2023 to a low of $25.5 million in Q1 2022.
• A 5-year average of $45.3 million and a median of $47.8 million in 2025 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue soared 463.66% in 2022 and retreated 22.12% in 2024, its largest moves.
• Tracing TXG's Cost of Revenue over 5 years: stood at $36.8 million in 2022, then surged by 85.18% to $68.2 million in 2023, then decreased by 20.72% to $54.1 million in 2024, then fell by 2.0% to $53.0 million in 2025, then slipped by 15.7% to $44.7 million in 2026.
• Business Quant data shows TXG's Cost of Revenue at $44.7 million in Q1 2026, $53.0 million in Q4 2025, and $48.7 million in Q3 2025.